A Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
There is a concern on the risk of thyroid cancer associated with glucagon-like peptide-1 (GLP-1) analogs including liraglutide and exenatide. In this article, we review related experimental studies, clinical trials and observational human studies currently available. In rodents, liraglutide activated the GLP-1 receptors on C-cells, causing an increased incidence of C-cell neoplasia. Animal experiments with monkeys demonstrated no increase in calcitonin release and no C-cell proliferation after long-term liraglutide administration. Longitudinal 2-year data from clinical trials do not support any significant risk for the activation or growth of C-cell cancer in humans in response to liraglutide. However, an analysis of the FDA adverse event reporting system database suggested an increased risk for thyroid cancer associated with exenatide after its marketing. Noticeably, a recent study discovered that GLP-1 receptor could also be expressed in human papillary thyroid carcinomas (PTC), but the impact of GLP-1 analogs on PTC is not known. Therefore, GLP-1 analogs might increase the risk of thyroid C-cell pathology in rodents, but its risk in humans awaits confirmation. Since GLP-1 receptor is also expressed in PTC besides C-cells, it is important to investigate the actions of GLP-1 on different subtypes of thyroid cancer in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“but these effects are smaller in humans.5”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 1×
“For examples some clinical trials have suggested an association between pioglitazone and bladder cancer [26, 27].”
BackgroundGiovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366 · cited 1×
“Hindawi Publishing Corporation Experimental Diabetes Research Volume 2012, Article ID 924168, 7 pages doi:10.1155/2012/924168 Review Article”
BackgroundInfluentialNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 4×
“While GLP-1 analogs can efficiently reduce blood glucose level in patients with type-2 diabetes [3, 4], they may potentially have adverse effects on thyroid glands because GLP-1 receptors are expressed in thyroid glands of humans [10] as well as in those of rodents [11].”
BackgroundInfluentialVigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0087 · Cited by 1,009
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882 · cited 1×
“Glucagon-like peptide-1 (GLP-1) is an incretin hormone released after meals by L cells in the ileum [1].”
BackgroundKnudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700 · cited 1×
“Hindawi Publishing Corporation Experimental Diabetes Research Volume 2012, Article ID 924168, 7 pages doi:10.1155/2012/924168 Review Article”
BackgroundInfluentialBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Hay, I. D. (1990) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30310-4 · Cited by 634
Research works printed but not linked: 1
- 10.1210/en.137.9.3674 · doi:10.1210/en.137.9.3674 · Paper page
Cited by
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
“Consequently, it is essential to carefully follow up diabetic patients exposed to long-term GLP-1 analogues for any incidence of thyroid cancer [184].”
BackgroundPanickar, K. S. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200431 · Cited by 126
Silverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15382 · Cited by 113
“As an exploratory post hoc analysis, we also grouped all the thyroid cancers excluding those reported as MTCs, observing a significant effect of GLP-1RA treatment (MH-OR 1.51 [95% CI 1.00, 2.29]; P = 0.05, FIGURE 1 Risk of overall thyroid cancers in patients receiving glucagon-like peptide-1 receptor agonist (GLP-1RA)…”
InfluentialDigging deeper through glucose metabolism and its regulators in cancer and metastasis
Ghanavat, M., Shahrouzian, M., Zayeri, Z. D., Banihashemi, S., Kazemi, S. M., & Saki, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118603 · Cited by 103
Effects of glucagon-like peptide-1 receptor agonists on renal function
Filippatos, T. D., & Elisaf, M. S. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i5.190 · Cited by 97
Semaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86
Dong, Y., Lv, Q., Li, S., Wu, Y., Li, L., Li, J., Zhang, F., Sun, X., & Tong, N. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.11.009 · Cited by 71
On-target Effects of GLP-1 Receptor Agonists on Thyroid C-cells in Rats and Mice
Rosol, T. J. (2013) · Toxicologic Pathology · doi:10.1177/0192623312472402 · Cited by 61
“…Increased diffuse C-cell proliferation Increased focal C-cell proliferation Increased C-cell adenomas Increased C-cell carcinomas The mode of action, for the most part, has been supported by experimental data (Bjerre Knudsen et al. 2010; Chiu, Shih, and Tseng 2012; Madsen et al. 2012a).”
BackgroundCD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology
Kawakita, E., Koya, D., & Kanasaki, K. (2021) · Cancers · doi:10.3390/cancers13092191 · Cited by 66
Roy, S., Ghosh, A., Majie, A., Karmakar, V., Das, S., Dinda, S. C., Bose, A., & Gorain, B. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155638 · Cited by 64
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
“Therefore, a potential risk of clinical development of thyroid cancer of either MTC or PTC (either from preexisting occult cancer or newly developed cancer) after repetitive stimulation by incretin-based therapies could be of concern.”
BackgroundInfluentialSelf-citationMannucci, E., Mosenzon, O., & Avogaro, A. (2016) · Diabetes Care · doi:10.2337/dcs15-3024 · Cited by 48
“Finally, it has been observed in preclinical studies that the incidence of thyroid C-cell tumors is increased in rodents treated with GLP-1 analogs (35).”
BackgroundMali, G., Ahuja, V., & Dubey, K. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13259 · Cited by 44
Eftekhari, S., Montazeri, H., & Tarighi, P. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173102 · Cited by 43
A Review on Thiazolidinediones and Bladder Cancer in Human Studies
Tseng, C. (2014) · Journal of Environmental Science and Health Part C · doi:10.1080/10590501.2014.877645 · Cited by 43
Self-citationGlucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
Lisco, G., De Tullio, A., Disoteo, O., Piazzolla, G., Guastamacchia, E., Sabbà, C., De Geronimo, V., Papini, E., & Triggiani, V. (2023) · Endocrine Connections · doi:10.1530/ec-23-0257 · Cited by 37
“…incident discovery of thyroid carcinomas could have been only a concomitant phenomenon (e.g. increased surveillance of thyroid nodules), or instead, the GLP-1RAs per se could have stimulated the proliferation of intra-thyroid preneoplastic lesions by acting as promoting factors (13, 14, 15, 16).”
Nassar, M., Nassar, O., Abosheaishaa, H. M., & Misra, A. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02466-4 · Cited by 35
Schwasinger-Schmidt, T. E., Robbins, D. C., Williams, S. J., Novikova, L., & Stehno‐Bittel, L. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.07.005 · Cited by 35
Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes
Tseng, C. (2016) · Oncotarget · doi:10.18632/oncotarget.8399 · Cited by 37
“Incretin-based therapies in patients with type 2 diabetes mellitus by using either the injection form of glucagon-like peptide-1 receptor (GLP-1R) agonists or the oral form of dipeptidyl peptidase-4 (DPP-4) inhibitors have been shown to increase the risk of thyroid cancer [1, 2].”
BackgroundResultSelf-citationEffect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man
Boess, F., Bertinetti-Lapatki, C., Zoffmann, S., George, C., Pfister, T., Roth, A., Lee, S. M. L., Thasler, W. E., Singer, T., & Suter, L. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0186 · Cited by 29
“…it is still controversial whether C-cell proliferative lesions observed http://jme.endocrinology-journals.org 2013 Society for Endocrinology DOI: 10.1530/JME-12-0186 Printed in Great Britain in rodents following chronic GLP1R agonist treatment are relevant to man (Capen 2008, Chiu et al. 2012).”
BackgroundInfluentialDulaglutide: A Review in Type 2 Diabetes
Burness, C. B., & Scott, L. J. (2015) · BioDrugs · doi:10.1007/s40259-015-0143-4 · Cited by 33
“There is concern around the risk of thyroid cancer associated with GLP-1 receptor agonists [49].”
BackgroundThe Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
Anala, A. D., Saifudeen, I. S. H., Ibrahim, M., Nanda, M., Naaz, N., & Atkin, S. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144575 · Cited by 39
Otolaryngologic Side Effects of GLP ‐1 Receptor Agonists
Khan, F. I., Vazquez, S. G., Mehdi, Z., Somawardana, I. A., Dongre, R., Razmi, S. E., Rashidi, K., Shenoi, J., Khan, N. S., Dhanda, A. K., et al. (2025) · The Laryngoscope · doi:10.1002/lary.32061 · Cited by 32
Funch, D., Mortimer, K., Ziyadeh, N. J., Seeger, J. D., Zhou, L., Ng, E., Ross, D., Major-Pedersen, A., Bosch-Traberg, H., Gydesen, H., et al. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s305496 · Cited by 24
“Generalized estimating equations (GEE) with exchangeable correlation structures and robust variance estimators accounted for the paired nature of the data created by matching, except where data were too sparse to support GEE.23 In a latency analysis, person-time and TC cases from the first year of follow-up were exclu…”
BackgroundInfluentialDiabetes, insulin use, smoking, and pancreatic cancer mortality in Taiwan
Tseng, C. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0471-0 · Cited by 24
“For example, metformin [9, 14, 16, 20] may reduce, while insulin and sulfonylureas [8, 14, 17, 21] may increase the risk.”
BackgroundSelf-citationNew Approaches to Feline Diabetes Mellitus: Glucagon-like peptide-1 analogs
Gilor, C., Rudinsky, A. J., & Hall, M. J. (2016) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x16660441 · Cited by 26
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes
Sheth, K., Kim, S., Porterfield, L. R., Virani, S. S., Wadhwani, S., & Vaughan, E. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01319-6 · Cited by 21
“Rodent studies and one observational study in humans have raised concerns about GLP-1RA’s impact on thyroid cancer risk; however, randomized controlled trials and a large international cohort study have shown no increases in thyroid cancer risk in humans [81–83].”
Adverse Effects Associated With Newer Diabetes Therapies: A Review Article
Akiyode, O., & Adesoye, A. A. (2015) · Journal of Pharmacy Practice · doi:10.1177/0897190015594732 · Cited by 23
Kupnicka, P., Król, M., Żychowska, J., Łagowski, R., Prajwos, E., Surówka, A., & Chlubek, D. (2024) · Pharmaceuticals · doi:10.3390/ph17111470 · Cited by 26
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors
Lacroix, A., Bourdeau, I., Chasseloup, F., Kamenický, P., Lopez, A.-G., Louiset, E., & Lefèbvre, H. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00200-6 · Cited by 19
Łuniewski, M., Matyjaszek‐Matuszek, B., & Lenart-Lipińska, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134431 · Cited by 16
Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial
Yammine, L., Kosten, T. R., Cinciripini, P. M., Green, C. E., Meininger, J. C., Minnix, J. A., & Newton, T. F. (2018) · Medicine · doi:10.1097/md.0000000000009567 · Cited by 16
Roy, D., Chadwick, K. D., Tatarkiewicz, K., LaCerte, C., Bergholm, A., Brodie, T., Mangipudy, R. S., Parkes, D. G., Graziano, M. J., & Reilly, T. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12294 · Cited by 13
“Yet, the same GLP-1 receptor agonists, and recently a DPP4 inhibitor (alogliptin), were shown to be associated with a drug-related c-cell thyroid neoplasia signal in rodents (presumably through the GLP-1 receptor on thyroid ccells) [75,76] supporting the validity of rodent carcinogenicity studies in identifying long a…”
BackgroundSaito, A., Kitayama, J., Horie, H., Koinuma, K., Kawashima, R., Ohzawa, H., Yamaguchi, H., Kawahira, H., Mimura, T., Lefor, A. K., et al. (2021) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0042 · Cited by 14
GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control
Nomiyama, T., & Yanase, T. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1191349 · Cited by 14
“Thyroid cancer was the first cancer in which GLP-1 action was investigated [31].”
BackgroundModels and Strategies in the Development of Antiobesity Drugs
Agahi, A., & Murphy, K. G. (2013) · Veterinary Pathology · doi:10.1177/0300985813492801 · Cited by 11
“There is also an increased incidence of thyroid cell hyperplasia and tumors in rodents treated with liraglutide,(83) but as yet there are no data as to whether there are similar effects in humans.(33)”
BackgroundDiabetes and thyroid cancer mortality: a 12‐year prospective follow‐up of Taiwanese
Tseng, C. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12086 · Cited by 10
Self-citationWilcox, L., & Dril, E. V. (2024) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2024.102185 · Cited by 12
New Incretin Hormonal Therapies in Humans Relevant to Diabetic Cats
Reusch, C. E., & Padrutt, I. (2013) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2012.11.003 · Cited by 9
The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease
Tsiampali, C., Papaioannidou, P., Goulas, A., & Pοlyzos, S. A. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2274536 · Cited by 10
“…thyroid cancer, they were observed in some animal studies, but was not shown to be clinically relevant in a meta-analysis [64]; however, GLP-1RAs are not recommended in individuals with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 [63,65].”
ResultImpaired glucose metabolism treatment and carcinogenesis
Matyszewski, A., Czarnecka, A. M., Kawecki, M., KORZEŃ, P., SAFIR, I. J., Kukwa, W., & Szczylik, C. A. (2015) · Oncology Letters · doi:10.3892/ol.2015.3324 · Cited by 7
“This effect may be due to increased GLP‐1 receptor‐dependent intracellular signaling transduction pathways (35-40,50).”
Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events?
Murphy, C. F., & le Roux, C. W. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.06 · Cited by 4
Koyagura, N., Im, N. N., Jamadar, M. G., Patil, A. M., & Anand, S. (2016) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2016.v9s2.13592 · Cited by 5
“GLP-1 mimetics can cause thyroid carcinoma [30].”
GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Pourkarim, F., & Entezari‐Maleki, T. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2311840 · Cited by 5
Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus
Hanefeld, M., Raccah, D., & Monnier, L. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1251579 · Cited by 5
Hollingshead, B. D., & Radi, Z. A. (2025) · Journal of Applied Toxicology · doi:10.1002/jat.4779 · Cited by 4
“These tumors are associated with the observed elevation in calcitonin levels, which leads to increased calcitonin-related gene expression and subsequent C-cell proliferation (Chiu et al. 2012 Pasternak et al. 2024).”
Disproportionality analysis of semaglutide-associated bile-duct cancer: A vigibase study
Kaur, R. J., Gomaz, S. B., Shaurya, R., Aggarwal, P., Porchezhian, P., Dhingra, S., Sidhu, P., Ambwani, S. R., & Charan, J. (2026) · Indian Journal of Gastroenterology · doi:10.1007/s12664-025-01891-4 · Cited by 4
Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
Xiao, Y., Meng, J., & Gao, S. (2024) · JAMA · doi:10.1001/jama.2024.2600 · Cited by 2
Semaglutide and weight management in the Arab countries: Focus on the United Arab Emirates
Semiz, S. (2025) · Health Sciences Review · doi:10.1016/j.hsr.2025.100244 · Cited by 2
Incretin for the continuing treatment of secondary failure to metformin in Type 2 diabetes
Gallwitz, B. (2013) · Diabetes Management · doi:10.2217/dmt.13.29 · Cited by 1
Pharmacologic management for polycystic ovary syndrome: Weight loss
Nadeem, S., & Merchant, A. A. H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87932-3.00025-6 · Cited by 1
GI Peptides, Energy Balance, and Cancer
Bruno, D. S., & Wolfe, M. M. (2016) · Energy balance and cancer · doi:10.1007/978-3-319-41677-9_11
Thyroid Hormone Homeostasis in Weight Loss and Implications for Bariatric Surgery
Sweeney, L. B., Campos, G. M., & Celi, F. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804011-9.00047-9
Taşkıran, B., & Cansu, G. B. (2017) · OSMANGAZİ JOURNAL OF MEDICINE · doi:10.20515/otd.308303
“In vitro sıçan ve farelerde eksenatid ile C hücrelerinde bulunan GLP-1 reseptörlerinin uyarılması sonucu Ct salınımı ve Ct gen ekspresyonu artar ve CHH gelişir (8,9).”
Zoltán, K. I., Kun, I., & Kolcsár, M. (2019) · Orvostudományi Értesítö · doi:10.2478/orvtudert-2019-0016 · Cited by 1
Glucagon-like peptide-1 receptor agonists : A new step towards weight management
Omar, M. (2023) · American Journal of Medical and Clinical Research & Reviews · doi:10.58372/2835-6276.1073
Jaradat, J. H., Alahmad, R., Jaghbeer, M. A., Abdelaziz, A. A., Afifeh, N. A., Afifeh, G. A., Rao, A., Alzoubi, A., & Nashwan, A. J. (2025) · Cureus · doi:10.7759/cureus.96071 · Cited by 3
Deng, C.-X., Chen, Z.-M., Tang, Y.-X., Xi, Z.-X., Wang, S.-Y., Wu, H.-Y., Xu, B., & Xu, T.-C. (2026) · World Journal of Pharmacology · doi:10.5497/wjp.v15.i1.113080
Elmezayen, Z. W., Qrareya, F., Abdallah, A., Salameh, H., & Qaisi, W. (2026) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514261443862
“…liraglutide can induce C-cell hyperplasia and increase the risk of C-cell tumors in animal models, with an associated rise in calcitonin levels, 8 but recent observational studies have demonstrated the absence of this hypothesized association between GLP-1 Receptor Agonists and thyroid cancers.”
Hsieh, H., Huang, Y., Chang, Y.-W., & Liao, W. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261460619
Association of Glucagon‐Like Peptide—1 Receptor Analogues and Laryngeal Symptoms in Obese Adults
Shah, P., Kayekjian, D., Nguyen, S. A., Meenan, K. D., & O’Rourke, A. K. (2026) · The Laryngoscope · doi:10.1002/lary.70808
Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies
Kounatidis, D. C., Vallianou, N. G., Kouveletsou, M., Kontrafouri, P., Stamatopoulos, V., Rebelos, E., Diakoumopoulou, E., & Dalamaga, Μ. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00770-z
“However, the translational relevance is uncertain because GLP-1R expression appears minimal in human thyroid C-cells [185].”
Metadata
- Authors
- Chiu, W.-Y., Shih, S.-R., & Tseng, C.-H.
- Affiliations
- National Taiwan University (TW)
- Corresponding author
- Tseng, Chin-Hsiao
- Venue
- Experimental Diabetes Research
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-7
- ISSN
- 1687-5214 (ISSN-L)
- 1687-5303
- PMC
- PMC3368340
- OpenAlex
- W2020816546
- Cited by
- 63
- References
- 35
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 6 · 2023: 9 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 8 · 2015: 4 · 2014: 3 · 2013: 10 · 2012: 1
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Experimental Diabetes Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Keywords
- GLP-1 receptor agonists, thyroid cancer, liraglutide, exenatide, GLP-1 receptor, drug safety, adverse drug reactions, calcitonin, type 2 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Animals, Clinical Trials as Topic, Diabetes Mellitus, Disease Models, Animal, Gene Expression Regulation, Humans, Macaca fascicularis, Peptides, Thyroid Neoplasms, Venoms, Receptors, Glucagon, Diabetes Complications, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.